Castrate resistant prostate cancer: New therapeutic approaches

	Tweet

Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden.

“If we look at the way kidney cancer treatment has changed over recent years we see a glimpse of the future”, says Dr Gleave, “Targeted therapies may become available”.

Recent studies indicate that tumour cells can develop an ability to synthesise enzymes to produce their own androgens for androgen receptor (AR) activation after castration. 

CRPC tumours are not uniformly hormone resistant and may remain sensitive to therapies directed against the ARs. Dr Gleave: “Several new classes of AR-targeting agents are now in clinical development, including the 2nd generation anti-androgen MDV3100, abiraterone, and Hsp27 (OGX-427)”.

The growth of new blood vessels, angiogenesis, plays an essential role in prostate cancer development and metastasis. “Among the various angiogenic targets implicated in tumour angiogenesis, vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, and its receptor have evoked a lot of interest,” according to Dr Gleave. Bevacizumab targets VEGF and is a promising angiogenesis inhibitor in this indication. Other agents in late stage trials include sunitinib.

Clusterin is a stress-induced, multi-functional, molecular chaperone. A novel, phase I pre-prostatectomy trial defined the optimal biologically dose and toxicity parameters of OGX-011 with maximal knockdown of clusterin in prostate and lymph node tissues at the 640 mg dose level. A phase II study includes 81 men with CRPC to receive either docetaxel and OGX-11 (n=40) or docetaxel alone (n=41).

“All in all, we need to move forward with the momentum and continue to let biology guide treatment developments”, said Gleave, who also expressed his gratitude for being invited to speak at the 24th Annual EAU Congress.

###

Contact: lindy brouwer

European Association of Urology

RELATED STORIES:
Prostate cancer screening still unproven: report   Accurate Prostate Cancer Diagnosis Depends on Biopsy Location   Diet May Reduce Risk of Prostate Cancer   Prostate Cancer Etiology   Strict diet program may help prostate cancer   Baldness drug could mask prostate cancer marker   Prostate cancer may respond to more hormone therapy   Immunologic tests detect hidden prostate cancer   Serum lipid levels and I-PSS or Qol are not linked in prostatic hyperplasia   Does race, income predict prostate cancer outcome?   Fatherhood linked to prostate cancer risk   Study links acetaminophen to lower prostate cancer risk   Heavy men fare poorly with prostate cancer   Obesity raises risk of prostate cancer recurrence   New Finding Suggests Prostate Biopsy is Not Always Necessary   A low-carb diet may stunt prostate tumor growth   Why Prostate Cancer Patients Fail Hormone Deprivation   New, non-invasive prostate cancer test beats PSA in detecting prostate cancer, researchers report   Laser may reduce prostate surgery’s sexual side effects   Xenotropic murine leukemia virus-related virus may not be associated with human prostate cancer   Aspirin, Other NSAIDs, May Prevent or Delay Enlarged Prostate   Men Can Take Their Time to Decide on Prostate Cancer Treatment

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]